1 June 2024 - The June 2024 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The June issue of the Schedule includes several new/revised listings of note:

• Budesonide with eformoterol fumarate dihydrate (Bufomix Easyhaler) - new formulation
• Ivacaftor (Kalydeco) - new indication
• Medroxyprogesterone acetate (Depo-Provera) - new formulation
• Osimertinib mesylate (Tagrisso) - new indication
• Secukinumab (Cosentyx) - new indication

Read Summary of PBS changes